Cara Therapeutics Initiates Human Abuse Liability Trial of CR845
July 31, 2014 08:00 ET
|
Cara Therapeutics
Comparator will be pentazocine, a Schedule IV opioid receptor agonist with lower abuse potential than common opioids
Top-line data expected in fourth quarter of 2014
SHELTON, Conn., July...
Cara Therapeutics Earns Milestone Payment From Maruishi Pharmaceutical for Completion of Phase 1 Clinical Trial of I.V. CR845 in Japan
July 16, 2014 08:00 ET
|
Cara Therapeutics
SHELTON, Conn., July 16, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
Cara Therapeutics Announces Appointment of Robert Medve, M.D., as Chief Medical Officer
June 24, 2014 08:00 ET
|
Cara Therapeutics
SHELTON, Conn., June 24, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
Cara Therapeutics Initiates Phase Ia/Ib Trial of Tablet Formulation of Oral CR845 for the Treatment of Acute and Chronic Pain
June 18, 2014 08:00 ET
|
Cara Therapeutics
SHELTON, Conn., June 18, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
Cara Therapeutics Names Eric J. Vandal Vice President, Commercial Operations
June 02, 2014 08:00 ET
|
Cara Therapeutics
SHELTON, Conn., June 2, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...